EYPT, US30233G2093

EyePoint stock: Company posts $95.6 million Q3 loss

Published on 11/17/2026 at 22:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
EyePoint stock follows a sharper company focus on diabetic macular edema after third-quarter results. Phase 3 data are expected in early Q4 2027.

Key points for investors

  • EyePoint reported a third-quarter 2026 net loss of 95.6 million US dollars, compared with 59.7 million US dollars a year earlier.
  • The company is prioritizing its diabetic macular edema program after both Phase 3 wet AMD trials missed their primary endpoints.
  • Phase 3 COMO and CAPRI trials are fully enrolled, with top-line data expected in early Q4 2027.
EYPT, US30233G2093, Illustration mit AI erstellt.

EyePoint, Inc. reported third-quarter 2026 results on November 12, 2026, and outlined a strategic shift toward diabetic macular edema. The company posted a net loss of 95.6 million US dollars, or 1.07 US dollars per share, compared with a loss of 59.7 million US dollars, or 0.85 US dollars per share, in the year-earlier quarter, according to GlobeNewswire.

Revenue fell to 0.8 million US dollars from 1.0 million US dollars a year earlier. Operating expenses rose to 97.6 million US dollars from 63.0 million US dollars, driven mainly by the DURAVYU Phase 3 programs.

EyePoint prioritizes DME development

EyePoint said it will conclude the wet age-related macular degeneration program before the full second year of the LUGANO and LUCIA studies. Both trials missed their primary non-inferiority endpoints, although the company reported treatment-burden and anatomical-control benefits in secondary analyses.

The company is now concentrating resources on diabetic macular edema. Phase 3 COMO and CAPRI are fully enrolled with more than 550 patients, and top-line data are expected in early the fourth quarter of 2027. The Phase 2 VERONA study of DURAVYU 2.7 milligrams met its primary endpoint and showed a 7.1-letter improvement in best-corrected visual acuity at Week 24.

Cash position and operating costs

Cash, cash equivalents and marketable securities totaled 118 million US dollars at September 30, 2026. EyePoint expects an additional 10 million US dollars raised after quarter-end, together with planned operating adjustments, to fund operations into late the third quarter of 2027.

The strategic prioritization includes a workforce reduction of approximately 53% and is expected to generate annualized savings of approximately 30 million US dollars. EyePoint stock traded at 0.28 euros on Lang & Schwarz at 22:46 CET on Tuesday, November 17, 2026.

EyePoint company facts

  • Company: EyePoint, Inc.
  • ISIN: US30233G2093
  • Ticker: EYPT
  • Home exchange: Nasdaq
  • Lang & Schwarz quote: 0.28 euros at 22:46 CET on November 17, 2026
  • Business: Clinical-stage biopharmaceutical company focused on retinal diseases

The Nasdaq Composite provides the broader U.S. market setting.

More news and analyses on EyePoint stock

Disclaimer...
en | US30233G2093 | EYPT | boerse | 70528803 | bgmi